NCT06817889View on ClinicalTrials.gov

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Hematopoietic and Lymphatic System NeoplasmLymphomaMultiple MyelomaRespiratory Syncytial Virus Infection
Interventions
DRUG

Remdesivir

Given IV

OTHER

Survey Administration

Ancillary studies

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Nasal Swab

Undergo nasal swabs

Trial Locations (3)

77030

NOT_YET_RECRUITING

MD Anderson Cancer Center, Houston

91010

NOT_YET_RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER